D-cycloserine-naloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure

Experimental and Clinical Psychopharmacology

Volumn 11, Issue 3, 2003, Pages 237-246

  Oliveto, Alison ^a   Benios, Thania ^a   Gonsai, Kishorchandra ^a   Feingold, Alan ^a   Poling, James ^a   Kosten, Thomas R ^a  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; NALOXONE; OPIATE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; MAINTENANCE THERAPY; MALE; OPIATE ADDICTION; SYSTOLIC BLOOD PRESSURE;

ADULT; ANTIMETABOLITES; CYCLOSERINE; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PAIN MEASUREMENT;

EID: 0042574176     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.11.3.237     Document Type: Article

References (45)

1. Aghajanian, G. K. (1978, November 9). Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature, 276, 186-188.
2. Aghajanian, G. K., & Wang, Y. Y. (1991). Common alpha-2 and opiate effector mechanisms in the locus coeruleus: Intracellular studies in brain slices. Neuropharmacology, 26, 789-800.
3. Akaoka, H., & Aston-Jones, G. (1991). Opiate withdrawal-induced hyperactivity of locus coeruleus neurons is substantially mediated by augmented excitatory amino acid input. Journal of Neuroscience, 11, 3830-3839.
4. Belozertseva, I. V., Danysz, W., & Bespalov, A. Y. (2000). Short-acting NMDA receptor antagonist MRZ 2/576 produces prolonged suppression of morphine withdrawal in mice. Naunyn-Schmiedeberg's Archives of Pharmacology, 361, 573-577.
5. Bickel, W. K., Bigelow, G. E., Preston, K. L., & Liebson, I. A. (1989). Opioid drug discrimination in humans: Stability, specificity and relation to self-reported drug effect. Journal of Pharmacology and Experimental Therapeutics, 251, 1053-1063.
6. Bickel, W. K., Oliveto, A. H., Kamien, J. B., Higgins, S. T., & Hughes, J. R. (1993). A novel-response procedure enhances the specificity and sensitivity of a triazolam discrimination in humans. Journal of Pharmacology and Experimental Therapeutics, 264, 360-367.
7. Bristow, L. J., Hogg, J. E., & Hutson, P. H. (1997). Competitive and glycine/NMDA receptor antagonists attenuate withdrawal-induced behaviours and increased hippocampal acetylcholine efflux in morphine-dependent rats. Neuropharmacology, 36, 241-250.
8. Broers, B., Gilner, F., Dumont, P., & Mino, A. (2000). Inpatient opiate detoxification in Geneva: Follow-up at 1 and 6 months. Drug and Alcohol Dependence, 58, 85-92.
9. D'Souza, D. C., Gil, R., Cassello, K., Morrissey, K., Abi Saab, D., White, J., et al. (2000). IV glycine and oral D-cycloserine effects on plasma and CSF amino acids in healthy humans. Biological Psychiatry, 47, 450-462.
10. Ennis, M., & Aston-Jones, G. (1988). Activation of locus coeruleus from nucleus paragiganto-cellularis: A new excitatory amino acid pathway in brain. Journal of Neuroscience, 8, 3644-3657.
11. Gossop, M., Green, L., Phillips, G., & Bradley, B. (1989). Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. British Journal of Psychiatry, 154, 348-353.
12. Guitart, X., & Nestler, E. J. (1989). Identification of morphine and cyclic AMP-regulated phosphoproteins (MARPPS) in the locus coeruleus and other regions of the rat brain: Regulation by acute and chronic morphine. Journal of Neuroscience, 9, 4371-4387.
13. Jasinski, D. R. (1977). Assessment of the abuse potential of morphine-like drugs (methods used in man). In W. R. Martin (Ed.), Drug addiction I (pp. 197-258). New York: Springer-Verlag.
14. Jasinski, D. R., Johnson, R. E., & Kocher, T. R. (1985). Clonidine in morphine withdrawal: Differential effects on signs and symptoms. Archives of General Psychiatry, 42, 1063-1066.
15. Kamien, J. B., Bickel, W. K., Oliveto, A. H., Smith, B. J., Higgins, S. T., & Hughes, J. R. (1994). Triazolam discrimination by humans under a novel-response procedure: Effects of buspirone and lorazepam. Behavioural Pharmacology, 5, 315-325.
16. Kleber, H. D., Riordan, C. E., Rounsaville, B. J., Kosten, T. R., Charney, D. S., Gaspari, J., et al. (1985). Clonidine in outpatient detoxification from methadone maintenance. Archives of General Psychiatry, 42, 391-394.
17. Kogan, J. H., Nestler, E. J., & Aghajanian, G. K. (1992). Elevated basal firing rates and enhanced responses to 8-Br-cAMP in locus coeruleus neurons in brain slices from opiate-dependent rats. European Journal of Pharmacology, 211, 47-53.
18. Koob, G. F., Maldonado, R., & Stinus, L. (1992). Neural substrates of opiate withdrawal. Trends in Neurosciences, 15(5), 186-191.
19. Kosten, T. A., DeCaprio, J. L., & Rosen, M. I. (1995). The severity of naloxone-precipitated opiate withdrawal is attenuated by felbamate, a possible glycine antagonist. Neuropsychopharmacology, 13, 323-333.
20. Kosten, T. R., Rounsaville, B. J., & Kleber, H. D. (1985). Comparison of clinical ratings to self-reports of withdrawal during clonidine detoxification of opiate addicts. American Journal of Drug and Alcohol Abuse, 11, 1-10.
21. Martin, W. R., Sloan, J. W., Sapiro, J. D., & Jasinski, D. R. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12, 245-258.
22. Mayer, M. L., & Miller, R. J. (1990). Excitatory amino acid receptors, 2nd messengers and regulation of intracellular Ca2+ in mammalian neurons. Trends in Pharmacological Sciences, 11, 254.
23. McEvoy, G. (Ed.). (2000). American Hospital Formulary Service drug information 2000. Bethesda, MD: Board of the American Society of Health-System Pharmacists American Hospital Formulary Service.
24. Medvedev, I. O., Dravolina, A., & Bespalov, A. Y. (1998). Effects of N-methyl-D-aspartate receptor antagonists on discriminative stimulus effects of naloxone in morphine-dependent rats using the Y-maze drug discrimination paradigm. Journal of Pharmacology and Experimental Therapeutics, 286, 1260-1268.
25. Nestler, E. J. (1992). Molecular mechanisms of drug addiction. Journal of Neuroscience, 12, 2439-2450.
26. Oliveto, A. H., Bickel, W. K., Kamien, J., Hughes, J. R., & Higgins, S. T. (1994). Effects of diazepam and hydromorphone in triazolam-trained humans under a novel-response drug discrimination procedure. Psychopharmacology, 114, 417-423.
27. Oliveto, A. H., Rosen, M., Kosten, T. A., Hameedi, F., Woods, S., & Kosten, T. R. (1998). Naloxone discrimination in opioid-dependent humans under a novel-response discrimination procedure. Experimental and Clinical Psychopharmacology, 6, 169-178.
28. Oliveto, A., Sevarino, K., McCance-Katz, E., Benios, T., Poling, J., & Feingold, A. (2003). Clonidine and yohimbine in opioid-dependent humans under a naloxone novel-response discrimination procedure. Behavioural Pharmacology, 14, 97-110.
29. Oliveto, A., Sevarino, K., McCance-Katz, E., & Feingold, A. (2002). Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacology Biochemistry and Behavior, 71, 85-96.
30. Physicians' desk reference. (1991). Oradell, NJ: Medical Economics.
31. Popik, P., Mamczarz, J., Fraczek, M., Widla, M., Hesselink, M., & Danysz, W. (1998). Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology, 37, 1033-1042.
32. Preston, K. L., Bigelow, G. E., Bickel, W. K., & Liebson, I. A. (1987). Three-choice drug discrimination in opioid-dependent humans: Hydromorphone, naloxone and saline. Journal of Pharmacology and Experimental Therapeutics, 243, 1002-1009.
33. Preston, K. L., Bigelow, G. E., Bickel, W. K., & Liebson, I. A. (1989). Drug discrimination in human post-addicts: Agonist-antagonist opioids. Journal of Pharmacology and Experimental Therapeutics, 250, 184-196.
34. Preston, K. L., Bigelow, G. E., & Liebson, I. A. (1990). Discrimination of butorphanol and nalbuphine in opioid-dependent subjects. Pharmacology Biochemistry and Behavior, 37, 511-522.
35. Rasmussen, K., & Aghajanian, G. K. (1989). Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: Attenuation by lesions of the nucleus paragigantocellularis. Brain Research, 505, 346-350.
36. Rasmussen, K., Beitner-Johnson, D., Krystal, J. H., Aghajanian, G. K., & Nestler, E. J. (1990). Opiate withdrawal and the rat locus coeruleus: Behavioral, electrophysiological, and biochemical correlates. Journal of Neuroscience, 10, 2308-2317.
37. Redmond, D. E., & Krystal, J. H. (1984). Multiple mechanisms of withdrawal from opioid drugs. Annual Review of Neuroscience, 7, 443-478.
38. Rosen, M. I., & Kosten, T. R. (1997). The effect of cycloserine on naloxone-precipitated opiate withdrawal. NIDA Research Monographs, 178, 308.
39. Rounsaville, B. J., Kosten, T. R., & Kleber, H. D. (1985). Success and failure at outpatient opioid detoxification: Evaluating the process of clonidine and methadone-assisted withdrawal. Journal of Nervous & Mental Disease, 173, 103-110.
40. San, L., Cami, J., Peri, J. M., Mata, R., & Porta, M. (1990). Efficacy of clonidine, guanfacine, and methadone in the rapid detoxification of heroin addicts: A controlled clinical trial. British Journal of Addiction, 85, 141-147.
41. Taylor, J. R., Elsworth, J. D., Garcia, E. J., Grant, S. J., Roth, R. H., & Redmond, D. E. (1988). Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology, 96, 121-134.
42. van Berckel, B. N., Lipsch, C., Gispen-de Wied, C., Wynne, H. J., Blankenstein, M. A., van Ree, J. M., & Kahn, R. S. (1998). The partial NMDA agonist D-cycloserine stimulates LH secretion in healthy volunteers. Psychopharmacologia, 138, 190-197.
43. van Berckel, B. N., Lipsch, C., Timp, S., Gispen-de Wied, C., Wynne, H. J., van Ree, J. M., & Kahn, R. S. (1997). Behavioral and neuroendocrine effects of the partial NMDA agonist D-cycloserine in healthy subjects. Neuropsychopharmacology, 16, 317-324.
44. Winer, B. J. (1962). Statistical principals in experimental design. New York: McGraw-Hill.
45. Zweben, J. E., & Payte, J. T. (1990). Methadone maintenance in the treatment of opioid dependence: A current perspective. Western Journal of Medicine, 152, 588-599.